JSP191-Based Conditioning

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
40 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Tags
Allogeneic Stem Cell Transplant, Monoclonal Antibody
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1734
NCT Identifier
NCT05907746

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.